Chloroquine/lopinavir/ritonavirDrug (lopinavir) plasma concentration increased following drug interaction and off-label use: 11 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1957卷 / 1期

关键词：

D O I：

10.1007/s40278-023-39266-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：141 / 141

相关论文

共 50 条

[1] Chloroquine/lopinavir/ritonavir/umifenovirQTc interval prolongation, drug interaction and off-label use: 2 case reports
Reactions Weekly, 2020, 1817 (1) : 112 - 112
[2] Lopinavir/ritonavirDrug-induced liver injury following off-label use: case report
Reactions Weekly, 2023, 1960 (1) : 266 - 266
[3] Lopinavir/ritonavirCardiotoxicities following off-label use: 4 case reports
Reactions Weekly, 2021, 1843 (1) : 229 - 229
[4] Lopinavir/ritonavir/tocilizumabHypertriglyceridaemia following off-label use: 2 case reports
Reactions Weekly, 2020, 1824 (1) : 180 - 180
[5] Lopinavir/ritonavirLack of efficacy following off-label use: 2 case reports
Reactions Weekly, 2022, 1903 (1) : 225 - 225
[6] Hydroxychloroquine/lopinavir/ritonavirDrug ineffectiveness following off-label use in COVID-19 infection: case report
Reactions Weekly, 2022, 1905 (1) : 239 - 239
[7] Lopinavir/ritonavirHyperlipidaemia following off-label use: case report
Reactions Weekly, 2020, 1828 (1) : 303 - 303
[8] Lopinavir/ritonavirBradyarrhythmia following an off-label use : case report
Reactions Weekly, 2020, 1832 (1) : 186 - 186
[9] Lopinavir/ritonavirWorsening of liver injury following off-label use: 7 case reports
Reactions Weekly, 2020, 1833 (1) : 239 - 239
[10] Lopinavir/ritonavirAcute kidney injury following off-label use: 8 case reports
Reactions Weekly, 2020, 1834 (1) : 154 - 154

← 1 2 3 4 5 →